Aratana Therapeutics Inc

Aratana Therapeutics — Stifel Dental & Veterinary Conference 2019

14 slides from Aratana Therapeutics's conference presentation, May 29, 2019

  1. Slide 1: Stifel Dental & Veterinary Conference May 29, 2019

    Stifel Dental & Veterinary Conference May 29, 2019

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Special Note Regarding Forward-Looking Statements This presentation contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) and reflects Aratana’s current beliefs. However, as with any pharmaceutical product, there a

  3. Slide 3: Our Executive Team

    Our Executive Team Craig Tooman Ernst Heinen, DVM, Ph.D. John Ayres, J.D. President & Chief Executive Officer Chief Development Officer Vice President of Corporate Development and Administration; General Counsel & Secretary Rhonda Hellums Chris Ready Chief Financial Officer & Treasurer Vice Presiden

  4. Slide 4: Our Accomplishments: innovative, best-in-class therapeutics

    Our Accomplishments Our team is well-respected in the industry and valued by our customers We deliver innovative, best-in-class therapeutics Unique ability to quickly and effectively develop scientifically differentiated therapeutics Therapeutic profiles superior to the standard of care therapy Reco

  5. Slide 5: Our Accomplishments: comprehensive service to veterinarians

    Our Accomplishments Our team is well-respected in the industry and valued by our customers We provide comprehensive service to veterinarians Relationship-driven selling allows us to partner with veterinarians Veterinarians are business owners and our therapeutics are practice-building Our therapeuti

  6. Slide 6: Our Accomplishments: innovation, growth potential and collaborator of choice

    Our Accomplishments Our team is well-respected in the industry and valued by our customers We are recognized for our innovation, growth potential and as a collaborator of choice Reputation for serving as a strong collaborator with human and animal health companies Received recognition nationally and

  7. Slide 7: Our Proven Development Successes

    Our Proven Development Successes Intersecting market opportunity & veterinarian needs with scientifically differentiated therapeutics Compelling Market Prevalent or high incidence to support opportunity Recognizable need Conditions or diseases without treatment options or outdated options Highly dif

  8. Slide 8: Fast-Tracked Innovation

    Fast-Tracked Innovation Early de-risking allows for efficient R&D efforts SAR Chemistry, Selection of Lead Animal Toxicology Animal PK In vitro Toxicology IND Filing Chemistry Optimization NDA Proof of Concept PK API and Formulation Development Dose Selection Potential for Probe Safety approvals in

  9. Slide 9: Practice-Changing Pet Therapeutics

    Practice-Changing Pet Therapeutics First-in-class therapeutic blocks the EP4 receptor, a primary mediator of canine OA pain and inflammation Available for our dogs before humans GALLIPRANT is dispensed by more clinics than any other oral NSAID1 Development and commercialization agreement with Elanco

  10. Slide 10: Our Financials

    Our Financials 10

  11. Slide 11: Revenues from Therapeutics

    Revenues from Therapeutics NOCITA & ENTYCE net product sales; GALLIPRANT licensing & collaboration revenues $ 1.9M $2.5M $ 1.5M $ 1.8M $2.3M $1.1M $ 0.7M $ 0.3M $0.6M $0.1M Q4 2016 Q1 2017 Q2 2017 Q3 2017 2 Q4 2017 Q1 2018 Q2 2018 Q3 2018 3 Q4 2018 Q1 2019 GALLIPRANT licensing & collaboration revenu

  12. Slide 12: Key Pipeline Programs

    Key Pipeline Programs On-going review of CMC technical section; on-going pivotal effectiveness study AT-002 (capromorelin) Management of weight loss in cats with chronic kidney disease Pivotal field effectiveness study is on-going for cat-specific formulation; anticipate completing target enrollment

  13. Slide 13: Aratana At-A-Glance

    Aratana At-A-Glance Revenue growth across portfolio Increasingly active account base Solid cash position Highly respected team of experts $7.4 million in net revenues from net product sales and licensing & collaboration revenues in first quarter 2019 Number of ordering accounts and activity in accou

  14. Slide 14: Delivering best-in-class therapeutics that improve the lives of our pets.

    Delivering best-in-class therapeutics that improve the lives of our pets.

Aratana Therapeutics — Stifel Dental & Veterinary Conference 2019 on 6ix